Biagio Ricciuti1, Kathryn C Arbour2, Jessica J Lin3, Amir Vajdi4, Natalie Vokes1, Lingzhi Hong5, Jianjun Zhang5, Michael Y Tolstorukov4, Yvonne Y Li6, Liam F Spurr6, Andrew D Cherniack6, Gonzalo Recondo1, Giuseppe Lamberti1, Xinan Wang7, Deepti Venkatraman1, Joao V Alessi1, Victor R Vaz1, Hira Rizvi2, Jacklynn Egger2, Andrew J Plodkowski8, Sara Khosrowjerdi3, Subba Digumarthy3, Hyesun Park9, Nuno Vaz9, Mizuki Nishino9, Lynette M Sholl10, David Barbie1, Mehmet Altan5, John V Heymach5, Ferdinandos Skoulidis5, Justin F Gainor3, Matthew D Hellmann2, Mark M Awad11. 1. Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. 2. Department of Medicine, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center, New York, New York. 3. Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. 4. Department of Analytics and Informatics, Dana-Farber Cancer Institute, Boston, Massachusetts. 5. Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas. 6. Department of Analytics and Informatics, Dana-Farber Cancer Institute, Boston, Massachusetts; Cancer Program, Broad Institute of Harvard and Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts. 7. Harvard Graduate School of Arts and Sciences, Harvard University, Cambridge, Massachusetts; Department of Environmental Health, Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts. 8. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York. 9. Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts. 10. Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts. 11. Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Electronic address: mark_awad@dfci.harvard.edu.
Abstract
INTRODUCTION: STK11 and KEAP1 mutations (STK11 mutant [STK11MUT] and KEAP1MUT) are among the most often mutated genes in lung adenocarcinoma (LUAD). Although STK11MUT has been associated with resistance to programmed death-(ligand)1 (PD-[L]1) inhibition in KRASMUT LUAD, its impact on immunotherapy efficacy in KRAS wild-type (KRASWT) LUAD is currently unknown. Whether KEAP1MUT differentially affects outcomes to PD-(L)1 inhibition in KRASMUT and KRASWT LUAD is also unknown. METHODS: Clinicopathologic and genomic data were collected from September 2013 to September 2020 from patients with advanced LUAD at the Dana-Farber Cancer Institute/Massachusetts General Hospital cohort and the Memorial Sloan Kettering Cancer Center/MD Anderson Cancer Center cohort. Clinical outcomes to PD-(L)1 inhibition were analyzed according to KRAS, STK11, and KEAP1 mutation status in two independent cohorts. The Cancer Genome Atlas transcriptomic data were interrogated to identify differences in tumor gene expression and tumor immune cell subsets, respectively, according to KRAS/STK11 and KRAS/KEAP1 comutation status. RESULTS: In the combined cohort (Dana-Farber Cancer Institute/Massachusetts General Hospital + Memorial Sloan Kettering Cancer Center/MD Anderson Cancer Center) of 1261 patients (median age = 61 y [range: 22-92], 708 women [56.1%], 1065 smokers [84.4%]), KRAS mutations were detected in 536 cases (42.5%), and deleterious STK11 and KEAP1 mutations were found in 20.6% (260 of 1261) and 19.2% (231 of 1202) of assessable cases, respectively. In each independent cohort and in the combined cohort, STK11 and KEAP1 mutations were associated with significantly worse progression-free (STK11 hazard ratio [HR] = 2.04, p < 0.0001; KEAP1 HR = 2.05, p < 0.0001) and overall (STK11 HR = 2.09, p < 0.0001; KEAP1 HR = 2.24, p < 0.0001) survival to immunotherapy uniquely among KRASMUT but not KRASWT LUADs. Gene expression ontology and immune cell enrichment analyses revealed that the presence of STK11 or KEAP1 mutations results in distinct immunophenotypes in KRASMUT, but not in KRASWT, lung cancers. CONCLUSIONS: STK11 and KEAP1 mutations confer worse outcomes to immunotherapy among patients with KRASMUT but not among KRASWT LUAD. Tumors harboring concurrent KRAS/STK11 and KRAS/KEAP1 mutations display distinct immune profiles in terms of gene expression and immune cell infiltration.
INTRODUCTION: STK11 and KEAP1 mutations (STK11 mutant [STK11MUT] and KEAP1MUT) are among the most often mutated genes in lung adenocarcinoma (LUAD). Although STK11MUT has been associated with resistance to programmed death-(ligand)1 (PD-[L]1) inhibition in KRASMUT LUAD, its impact on immunotherapy efficacy in KRAS wild-type (KRASWT) LUAD is currently unknown. Whether KEAP1MUT differentially affects outcomes to PD-(L)1 inhibition in KRASMUT and KRASWT LUAD is also unknown. METHODS: Clinicopathologic and genomic data were collected from September 2013 to September 2020 from patients with advanced LUAD at the Dana-Farber Cancer Institute/Massachusetts General Hospital cohort and the Memorial Sloan Kettering Cancer Center/MD Anderson Cancer Center cohort. Clinical outcomes to PD-(L)1 inhibition were analyzed according to KRAS, STK11, and KEAP1 mutation status in two independent cohorts. The Cancer Genome Atlas transcriptomic data were interrogated to identify differences in tumor gene expression and tumor immune cell subsets, respectively, according to KRAS/STK11 and KRAS/KEAP1 comutation status. RESULTS: In the combined cohort (Dana-Farber Cancer Institute/Massachusetts General Hospital + Memorial Sloan Kettering Cancer Center/MD Anderson Cancer Center) of 1261 patients (median age = 61 y [range: 22-92], 708 women [56.1%], 1065 smokers [84.4%]), KRAS mutations were detected in 536 cases (42.5%), and deleterious STK11 and KEAP1 mutations were found in 20.6% (260 of 1261) and 19.2% (231 of 1202) of assessable cases, respectively. In each independent cohort and in the combined cohort, STK11 and KEAP1 mutations were associated with significantly worse progression-free (STK11 hazard ratio [HR] = 2.04, p < 0.0001; KEAP1 HR = 2.05, p < 0.0001) and overall (STK11 HR = 2.09, p < 0.0001; KEAP1 HR = 2.24, p < 0.0001) survival to immunotherapy uniquely among KRASMUT but not KRASWT LUADs. Gene expression ontology and immune cell enrichment analyses revealed that the presence of STK11 or KEAP1 mutations results in distinct immunophenotypes in KRASMUT, but not in KRASWT, lung cancers. CONCLUSIONS: STK11 and KEAP1 mutations confer worse outcomes to immunotherapy among patients with KRASMUT but not among KRASWT LUAD. Tumors harboring concurrent KRAS/STK11 and KRAS/KEAP1 mutations display distinct immune profiles in terms of gene expression and immune cell infiltration.
Authors: Shunsuke Kitajima; Tetsuo Tani; Benjamin F Springer; Marco Campisi; Tatsuya Osaki; Koji Haratani; Minyue Chen; Erik H Knelson; Navin R Mahadevan; Jessica Ritter; Ryohei Yoshida; Jens Köhler; Atsuko Ogino; Ryu-Suke Nozawa; Shriram K Sundararaman; Tran C Thai; Mizuki Homme; Brandon Piel; Sophie Kivlehan; Bonje N Obua; Connor Purcell; Mamiko Yajima; Thanh U Barbie; Patrick H Lizotte; Pasi A Jänne; Cloud P Paweletz; Prafulla C Gokhale; David A Barbie Journal: Cancer Cell Date: 2022-09-22 Impact factor: 38.585
Authors: Biagio Ricciuti; Xinan Wang; Joao V Alessi; Hira Rizvi; Navin R Mahadevan; Yvonne Y Li; Andrew Polio; James Lindsay; Renato Umeton; Rileen Sinha; Natalie I Vokes; Gonzalo Recondo; Giuseppe Lamberti; Marissa Lawrence; Victor R Vaz; Giulia C Leonardi; Andrew J Plodkowski; Hersh Gupta; Andrew D Cherniack; Michael Y Tolstorukov; Bijaya Sharma; Kristen D Felt; Justin F Gainor; Arvind Ravi; Gad Getz; Kurt A Schalper; Brian Henick; Patrick Forde; Valsamo Anagnostou; Pasi A Jänne; Eliezer M Van Allen; Mizuki Nishino; Lynette M Sholl; David C Christiani; Xihong Lin; Scott J Rodig; Matthew D Hellmann; Mark M Awad Journal: JAMA Oncol Date: 2022-08-01 Impact factor: 33.006
Authors: Myrto Moutafi; Sandra Martinez-Morilla; Prajan Divakar; Ioannis Vathiotis; Niki Gavrielatou; Thazin Nwe Aung; Vesal Yaghoobi; Aileen I Fernandez; Jon Zugazagoitia; Roy S Herbst; Kurt A Schalper; David L Rimm Journal: J Thorac Oncol Date: 2022-04-28 Impact factor: 20.121